Patents Assigned to Centers For Disease Control and Prevention
-
Publication number: 20200230227Abstract: The present invention relates to a recombinant antigen derived from Zika virus E protein and use thereof. Specifically, the present invention provides a polynucleotide encoding Zika virus E protein domain III alone or repeatedly three times, a recombinant plasmid vector comprising the polynucleotide, and a DNA vaccine composition that may induce an immune response to Zika virus by expressing a Zika virus antigen protein effectively. In addition, the present invention provides a neutralizing antibody against Zika virus obtained using the polynucleotide and a method for preparing the neutralizing antibody.Type: ApplicationFiled: December 10, 2019Publication date: July 23, 2020Applicant: Korea Center For Disease Control And PreventionInventors: You-Jin Kim, Hyun Ju In, HeeJi Lim, Sun-Dong Jang, Jung-Sik Yoo, Gyung Tae Chung
-
Patent number: 10695414Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.Type: GrantFiled: May 31, 2018Date of Patent: June 30, 2020Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and PreventionInventors: Olen M. Kew, Cara Carthel Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
-
Patent number: 10251948Abstract: Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating HIV infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against HIV in organism.Type: GrantFiled: January 21, 2015Date of Patent: April 9, 2019Assignee: National Center for AIDS/STD Control And Prevention, Chinese Center for Disease Control and PreventionInventors: Yiming Shao, Lianxing Liu, Rongxian Shen
-
Patent number: 10064933Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.Type: GrantFiled: August 3, 2016Date of Patent: September 4, 2018Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
-
Patent number: 10036076Abstract: Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.Type: GrantFiled: June 15, 2016Date of Patent: July 31, 2018Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and PreventionInventors: Stephen Lindstrom, Lamorris Loftin
-
Patent number: 9913892Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: October 6, 2014Date of Patent: March 13, 2018Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
-
Patent number: 9879232Abstract: The attenuated vaccinia virus strain KVAC103 was obtained by subculturing a vaccinia virus strain 103 times in VERO cells. The attenuated vaccinia virus strain KVAC103 has significantly low toxicity, shows reduced skin lesions, and, at the same time, induces effectively immune responses to poxvirus. Thus, it can be used as a poxvirus vaccine while causing less side effects.Type: GrantFiled: October 15, 2015Date of Patent: January 30, 2018Assignee: KOREA CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Sang Gu Yeo, Ho Sun Son, June Woo Lee, Seung Bin Cha, Sun Hwa Lee, Kwi Sung Park, Sang Won Lee
-
Patent number: 9879281Abstract: Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.Type: GrantFiled: October 15, 2015Date of Patent: January 30, 2018Assignee: KOREA CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Ho Sun Son, Sang Gu Yeo, Sang Won Lee
-
Patent number: 9879317Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.Type: GrantFiled: February 17, 2012Date of Patent: January 30, 2018Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb
-
Patent number: 9650422Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.Type: GrantFiled: March 16, 2015Date of Patent: May 16, 2017Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Gwong-Jen J. Chang, Wayne D. Crill
-
Patent number: 9487832Abstract: A process for detecting Neisseria meningitidis nucleic acid in a sample is provided including producing an amplification product by amplifying Neisseria meningitidis nucleotide sequence of the sodC gene or mRNA using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and detecting the amplification product to detect Neisseria meningitidis in the sample. Also provided are reagents and methods for detecting and distinguishing Neisseria meningitidis from other infectious agents. A kit is provided for detecting and quantifying Neisseria meningitidis in a sample.Type: GrantFiled: October 11, 2011Date of Patent: November 8, 2016Assignee: The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventor: Jennifer Thomas
-
Patent number: 9439935Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.Type: GrantFiled: January 24, 2014Date of Patent: September 13, 2016Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
-
Patent number: 9435000Abstract: Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.Type: GrantFiled: September 20, 2013Date of Patent: September 6, 2016Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Johns Hopkins UniversityInventors: William M. Switzer, Walid Heneine, Thomas M. Folks, Nathan D. Wolfe, Donald S. Burke, Eitel Mpoudi Ngole
-
Patent number: 9345758Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: April 19, 2011Date of Patent: May 24, 2016Assignees: University of Florida Research Foundation, Inc., The United States of America as represented by The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention, Cornell Research Foundation, Inc.Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, William L. Castleman, Nancy J. Cox
-
Patent number: 9310366Abstract: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.Type: GrantFiled: March 13, 2013Date of Patent: April 12, 2016Assignees: University of Georgia Research Foundation, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Russell W. Carlson, Geert-Jan Boons, Therese Buskas, Elmar Kannenberg, Alok Mehta, Elke Saile, Conrad Quinn, Patricia Wilkins, Mahalakshmi Vasan, Margreet A. Wolfert
-
Patent number: 9260746Abstract: This application provides photoinduced electron transfer (PET) nucleic acid molecules that can be used detect and amplify nucleic acid molecules, such as target nucleic acid molecules. These PET tags can be attached to the 5?-end of a target sequence-specific primer, thereby generating a PET primer. In particular examples, a PET tag includes a 5?-labeled nucleotide that can be quenched by at least two consecutive Gs within the tag sequence, and is unquenched when the PET tag hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using PET primers in nucleic acid amplification, such as real-time PCR.Type: GrantFiled: November 21, 2008Date of Patent: February 16, 2016Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Jothikumar Narayanan, Vincent Hill
-
Patent number: 9260762Abstract: Methods for detecting Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp. are disclosed. A sample suspected of containing a nucleic acid of one or more of M. pneumoniae, C. pneumoniae, and Legionella spp. is screened for the presence or absence of that nucleic acid. Determining whether the M. pneumoniae, C. pneumoniae, or Legionella spp. nucleic acid is present in the sample can be accomplished by detecting hybridization between a M. pneumoniae probe (such as a CARDS toxin probe), a C. pneumoniae probe (such as a ArgR probe), or a Legionella spp. probe (such as a SsrA probe) and a nucleic acid in a sample. Also disclosed are probes and primers for the detection of M. pneumoniae, C. pneumoniae, and Legionella spp., and kits that contain the disclosed probes and/or primers.Type: GrantFiled: April 15, 2011Date of Patent: February 16, 2016Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Jonas M. Winchell, Agnes Warner, Kathleen Thurman
-
Patent number: 9248179Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.Type: GrantFiled: June 23, 2011Date of Patent: February 2, 2016Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
-
Patent number: 9169298Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.Type: GrantFiled: October 25, 2011Date of Patent: October 27, 2015Assignees: Centers for Disease Control and PreventionInventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Patent number: 9163287Abstract: Processes for the serotype specific detection and identification of one or more Salmonella serotypes are provided. A family of specific primers and probes are provided that allow screening of biological or environmental samples for robust, rapid, and reproducible detection and identification of one or more Salmonella serotypes in the sample.Type: GrantFiled: October 26, 2011Date of Patent: October 20, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Patricia Fields, John R. McQuiston, Collette Fitzgerald Leaumont
Justia Legal Resources
